The Helsinki Sorbent: Why a Rare-Earth Separation Advance Matters More to Oncology Than to Mining

Highlights

• A new zirconia-based hybrid material grafted with aminomethylenephosphonate ligands achieves a La/Lu separation factor of 87.4, but its true value lies in purifying high-value medical radionuclides, not bulk rare-earth mining.
• The material's radiation tolerance and selectivity make it well-suited for lutetium-177 and other therapeutic isotope production, where small volumes, high purity demands, and radioactive feeds favor solid-phase extraction over conventional solvent extraction.
• Claims about e-waste recycling and bulk rare-earth supply security are plausible long-range ambitions but remain research directions, not near-term industrial solutions given throughput and cost constraints.
• The Am/Eu separation factor of up to 13 reported in a 2025 companion paper signals potential for nuclear-waste partitioning and actinide-based radiopharmaceuticals, though production-scale deployment still requires multistage optimization.
• Key metrics still missing from the public record—dynamic loading capacity, desorption kinetics under radioactive conditions, and regeneration lifetime—will determine whether this sorbent moves beyond the laboratory bench.

---

A new hybrid material out of the University of Helsinki has been framed as a cleaner way to separate rare earths and recycle them from e-waste. Read the chemistry closely, and the near-term value sits somewhere narrower and more interesting: the supply chain for cancer isotopes.

On 17 June 2026, Miho Otaki defended her doctoral dissertation in the Faculty of Science at the University of Helsinki, in Risto Koivula's Radiochemistry Unit. The accompanying press notice bundled three large promises under one material: cleaner rare-earth separation, recovery of rare earths from electronic waste, and a more secure supply of medical isotopes. All three are plausible long-range ambitions, but only one emerges from the published evidence as a near-term application. That application is not bulk rare-earth refining. It is radionuclide purification.

For readers tracking critical materials as an industrial, geopolitical, or healthcare theme, that distinction matters. The relevant question is not whether the chemistry is interesting; it is whether the material solves a bottleneck that existing process technology handles poorly. On the evidence now in public view, the clearest bottleneck is the purification of high-value radioactive lanthanides and related isotopes, not the tonnage economics of mining or e-waste recovery.

What was actually built

The Helsinki material is an inorganic-organic hybrid in which aminomethylenephosphonate ligands are chemically grafted onto a porous zirconium-oxide support. In the 2023 paper underpinning the dissertation, the team used commercial monoclinic zirconia pellets (Saint-Gobain NorPro SG85), then ground, sieved, and surface-functionalized them through a post-synthetic grafting route. The oxide provides chemical and mechanical durability, while the phosphonate ligand does the selective binding.

The central result is about ligand design rather than about zirconia as such. Otaki and co-authors compared four ligands with increasing numbers of aminomethylenephosphonate groups — ATMP, EDTMP, DTPMP, and TTHMP — and reported a broadly increasing pattern: adding more phosphonate groups tended to produce stronger intra-lanthanide selectivity, with the sharpest gains at the high end of the series. All of the hybrids showed lanthanide uptake of roughly 100 micromoles per gram at pH 3, but the most heavily phosphonated ligand delivered a La/Lu separation factor of 87.4 ± 9.8 in the full lanthanide mixture, with a binary La/Lu value of 29.8. Set against an earlier benchmark in this material family, where amino-tris(methylphosphonic acid) on zirconia produced a La/Eu separation factor of only 2.7, the contribution is clear, though the two figures describe different element pairs; the like-for-like La/Eu comparison runs from that 2.7 baseline to about 7.0 for the most phosphonated ligand. Either way, phosphonate density is a usable design lever for selectivity on a radiation-tolerant solid support.

Two methodological details make the immediate application easier to identify. First, the uptake studies used a carrier-free lutetium-177 tracer alongside stable lutetium, which connects the work to radiopharmaceutical purification workflows where no-carrier-added purity matters, even though the sorption tests themselves ran with stable carrier present rather than under strict no-carrier-added conditions. Second, the team moved beyond batch sorption tests to fixed-bed column experiments and reusability studies, which is the minimum threshold for discussing process relevance rather than laboratory curiosity.

Why the headline selectivity number needs caution

A separation factor above 80 sounds dramatic until one asks which pair was separated. Lanthanum and lutetium sit near opposite ends of the lanthanide series and differ significantly in ionic radius, making them a relatively favorable test case compared with the pairs that actually constrain industrial separations. The practical challenge in rare-earth refining lies in adjacent or near-adjacent pairs, where ionic radii differ by only a few hundredths of an angstrom, such as neodymium/praseodymium, europium/gadolinium, or, for isotope production, ytterbium/lutetium.

That means the key caveat is not whether the La/Lu result is real; it is whether it predicts performance on the chemically hardest separations. It does not yet do that. Any claim that the material enables selective separation "even among chemically similar elements" should therefore be judged against adjacent-pair performance under realistic process conditions, not against end-member separation across the full lanthanide series.

The more revealing selectivity result from the Helsinki program may be the 2025 companion paper by Hiltunen and colleagues, with Otaki among the authors, on americium/europium separation. That study reported an Am/Eu separation factor of up to 13 at pH 2 using heterocyclic bistriazolyl phosphonate ligands grafted onto zirconia and titania, with preference for americium even when europium was present in excess. Minor-actinide/lanthanide separation is one of the genuinely difficult problems in radiochemistry, relevant both to nuclear-waste partitioning and to purification routes for therapeutic radionuclides. Even so, a factor near 13 should be read as promising rather than definitive for production-scale deployment, because demanding process targets may still require multistage operation, optimization of kinetics, and careful control of working capacity.

Why this is chiefly an isotope story

The property that most clearly distinguishes the Helsinki material is not simply selectivity but stability under harsh conditions. Conventional solid-phase extraction resins are usually organic polymer systems, and both those resins and the organic diluents used in liquid-liquid extraction can degrade under ionizing radiation. By contrast, a metal(IV)-oxide support bearing phosphonate groups offers multiple Zr-O-P linkages and correspondingly stronger resistance to acidic and radiolytic stress, although performance in practice will still depend on total dose, dose rate, and solution chemistry.

For radioactive, or “hot,” feeds, that stability is not a secondary feature; it is often the decisive one. In bulk rare-earth separation, the incumbent technology remains multistage solvent extraction, which is mature, optimized, and deeply entrenched on cost despite its heavy use of hazardous liquids and repeated process stages. A grafted-zirconia sorbent operated in columns may reduce liquid waste and simplify some downstream handling, but solid-phase extraction has historically faced limits in throughput, mass-transfer rate, and working capacity that have kept it out of mainstream bulk refining.

Those disadvantages matter far less in medical radionuclide production. There, volumes are small, value per gram is extraordinarily high, the feed is radioactive by definition, and purity specifications are severe. This is exactly the operating regime in which a radiation-tolerant, selective, reusable sorbent can outperform conventional process choices on practicality rather than on tonnage economics.

Lutetium-177 is the clearest anchor case. The no-carrier-added production route begins with enriched ytterbium-176 targets, so a difficult Yb/Lu separation on radioactive material sits in the critical path to finished doses. The same logic extends to other medically relevant systems, including actinium-225 and terbium isotopes, where separation difficulty, radiological handling, and willingness to pay all favor highly selective solid-phase methods over conventional bulk-oriented chemistry.

That is the real beachhead. Not e-waste recycling, not substitution for mine-scale solvent-extraction trains, but the back end of radionuclide production where incumbent methods are operationally awkward and the cost of impurity is high.

What the supply-security case does and does not support

The supply-security angle is real, but narrower than the press framing suggests. A European, non-solvent purification route for medical radiolanthanides would strengthen isotope supply resilience in a field where enriched-target supply, irradiation access, and purification capacity are concentrated in relatively few hands. In that context, local separation capability can carry strategic value far beyond its physical tonnage.

The circular-economy claim should be treated more cautiously. Recovering rare earths from pre-treated e-waste with a selective sorbent is chemically plausible, but it runs into the same throughput and cost constraints that limit solid-phase extraction in bulk rare-earth refining. At this stage, it is better described as a research direction than as a near-term supply lever.

The metrics that now matter are unglamorous and specific. The public literature establishes laboratory-scale selectivity, initial column behavior, and some reusability. What will determine whether the material leaves the bench are dynamic loading capacity at realistic process concentrations, adsorption and desorption kinetics under radioactive conditions, regeneration lifetime over many cycles, and cost per cycle or per purified unit of activity.

Two-market judgment

Measured against bulk rare-earth refining, the Helsinki sorbent looks like a capable but incremental contribution to a long-running materials-chemistry effort. Nothing in the published record yet suggests that it will displace solvent-extraction incumbents in mine-scale or recycling-scale separation during this decade. The economics, throughput demands, and degree of process optimization required for that leap remain on the side of established technologies.

Measured against the medical-radionuclide supply chain, the same material looks more consequential. It targets a corner of the rare-earth world where volumes are small, margins are high, radiation tolerance matters acutely, and process simplicity can be more valuable than bulk throughput. The most defensible reading is therefore narrower than the headline but also more useful: this is an enabling separation technology for cancer-isotope supply chains, with a much longer and less certain path to any impact on bulk rare-earth markets.

References

M. Otaki, T. Suominen, V. Suorsa, S. Hietala, R. T. Koivula. "The effect of phosphonates on lanthanide separation for surface-grafted porous zirconia." Materials Advances, 2023, 4, 551–560. DOI: 10.1039/D2MA00928E.

O.-M. Hiltunen, T. Suominen, J. Aho, M. Otaki, A. Zupanc, S. Hietala, G. Silvennoinen, R. Koivula. "Selective separation of Am(III)/Eu(III) using heterocyclic bistriazolyl phosphonate grafted zirconia and titania solid phase extractants." RSC Applied Interfaces, 2025, 2, 279–291. DOI: 10.1039/D4LF00277F.

University of Helsinki. "New materials enable cleaner rare earth elements separation." News release accompanying the dissertation defense, 17 June 2026.